Secrets of regulatory T cell development reveal clinical possibilities
St. Jude scientists have identified key steps in production of the regulatory T cells that have a role in everything from autoimmune disorders to cancer.
SARS-CoV-2 vaccination creates a strong, persistent T-cell response
St. Jude Immunology study details how T cells respond to mRNA vaccination for SARS-CoV-2. Published in Cell, in collaboration with Washington University St. Louis.
Research reveals features that influence phase separation
St. Jude researchers reveal more details of processes cells use to organize the proteins within them, which may provide insight into neurological diseases and cancer.
Chromatin architecture reveals vulnerabilities to neurodegenerative movement disorders
St. Jude researchers showed why neurons called Purkinje cells in the cerebellum are particularly susceptible to DNA damage that goes unrepaired.
Phase separation underlies leukemia caused by NUP98 fusion oncoproteins
St. Jude scientists describe how a group of well-known fusion oncoproteins causes leukemia in the journal Cancer Discovery.
World Health Organization and St. Jude Children’s Research Hospital to dramatically increase global access to childhood cancer medicines
WHO and St. Jude will establish a platform to dramatically increase access to childhood cancer medicines in low- and middle-income countries
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
St. Jude phase II clinical trial results suggest monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
St. Jude at ASH: Annual hematology meeting highlights recent research
Researchers will present their work and share their expertise at ASH2021, the 63rd annual meeting of the American Society of Hematology.
Exhaustion affects CAR T–cell clinical response
Clinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses. St. Jude scientists' findings were published in Cell Reports.
Findings reveal new mechanism of activation for ALK
St. Jude Children’s Research Hospital scientists have shed light on the way ligands bind to and activate ALK, an important target for cancer drug development.
Discovery of how immune cells sense nutrients offers new therapeutic insight
St. Jude scientists map nutrient-dependent signaling in T cells, offering possible new drug targets for treating infectious diseases, cancer and immune-mediated disorders.
Target prevents T-cell exhaustion, boosts CAR T–cell responses
Findings from St. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.
St. Jude researchers are again among the world’s most highly cited scientists
The fourteen scientists are among the most highly cited investigators in the world during the past decade, reflecting the international reach of St. Jude research.
Safety concerns raised for neuroblastoma candidate drug
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Together by St. Jude Teaches Children about the COVID-19 Vaccines in New Coloring Book
Following FDA authorization of the COVID-19 vaccine for children ages 5 to 11, St. Jude releases a free coloring book that educates children on vaccines.
Cell-free DNA identifies early signs of relapse in pediatric medulloblastoma
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
Promising preclinical cancer therapy harnesses a newly discovered cell death pathway
Results offer clues for enhancing interferon effectiveness in cancer treatment.
Powered by St. Jude, Together, a web-based patient education resource on childhood cancer, plans to launch in seven new languages
Together by St. Jude announces plans to launch in seven new languages, offering trustworthy medical information about pediatric cancer and shared stories of hope to families around the world.
Accumulated DNA damage linked to neurodegeneration in a rare pediatric disorder
St. Jude Children’s Research Hospital scientists have identified the disease process that underlies Aicardi-Goutières syndrome, a debilitating illness with no known cure.
St. Jude acquires a facility dog for employee support
Rosalie, a 60-pound golden retriever, joins St. Jude as a facility dog in the Staff Resilience Center dedicated to supporting employees.
Genetic rescue, a ‘natural gene therapy,’ suggests possible new approach to pediatric MDS
St. Jude and the European Working Group of MDS in Childhood report results of a landmark study of the blood disorders known as pediatric myelodysplastic syndromes.
David Rogers honored by American College of Clinical Pharmacy
The chair of St. Jude Pharmacy/Pharmaceutical Sciences will receive 2 top science honors from ACCP at its annual meeting. It is highly unusual for both to be presented to the same person in the same year.
St. Jude names Shannon Dean, M.D., as chief medical information officer
Shannon Dean to help oversee launch of hospital’s new electronic health record as the hospital enhances the patient experience.
Control of rhabdomyosarcoma cell identity provides clues to possible treatments
Findings from St. Jude Children’s Research Hospital show how control of transcription factors by a common tumor suppressor gene may provide a therapeutic opportunity in a type of childhood cancer.
Research reveals new treatment strategy for propionic acidemia
Findings from St. Jude Children’s Research Hospital shed light on what drives this metabolic disease and provides clues to targeted treatment with pantazines.
Research provides evidence for how a key transcription factor manages access to DNA
St. Jude scientists have revealed a previously unknown role for CTCF, a pivotal transcription regulator linked to cancer.
The PANoptosome: a new frontier in innate immune responses
St. Jude scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.
St. Jude and leading cancer centers urge vaccination to protect against HPV and other diseases
NCI-designated cancer centers, AACI members and other cancer centers and medical groups endorse HPV vaccination and cancer screening to eliminate cancers caused by the virus.
COVID-19 in children with cancer: Severe disease and disrupted treatment
Scientists from St. Jude and the International Society of Paediatric Oncology report results from the Global Registry of COVID-19 and Childhood Cancer.
Bringing protein structures in from the cold
Findings from St. Jude show that protein structures obtained from cryogenic (frozen) techniques can lead to incorrect or missing information and throw off computational models.
Retinoblastoma resource: Researchers create more accurate research model
St. Jude Children’s Research Hospital scientists have created a model of the rare pediatric eye cancer that more closely mimics the biology of patient tumors.
New insight into red blood cell machinery offers clues to treating sickle cell disease
Scientists at St. Jude have uncovered how the body generates protective fetal hemoglobin against sickle cell disease and beta thalassemia.
Tennessee health care and public health leaders urge immediate action to protect state’s children from vaccine-preventable diseases
Measures proposed to address decline in adolescent vaccination associated with the COVID-19 pandemic.
Jose Fernandez named senior vice president of campus operations at St. Jude
Newly created position will oversee multiple departments and campus expansion.
International collaboration helps refine treatment for childhood leukemia
Vincristine and dexamethasone pulses can be safely eliminated from low-risk acute lymphoblastic leukemia treatment.
Comprehensive clinical sequencing opens door to the promise of precision medicine
St. Jude Children’s Research Hospital study highlights the power of comprehensive whole genome, whole exome and RNA sequencing to better understand and treat each patient’s cancer.
Research illuminates earliest part of phase separation
St. Jude scientists study how phase separation begins on a microsecond time scale, showing how the earliest events with individual molecules impact assembly speed.
Chemotherapy can induce mutations that lead to pediatric leukemia relapse
A collaboration led by St. Jude Children’s Research Hospital, Shanghai Children’s Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse.
Scientists link frailty and neurocognitive decline in childhood cancer survivors
St. Jude Children’s Research Hospital scientists have shown that frailty contributes to neurocognitive decline in young adult survivors of childhood cancer.
Bill Greene, PharmD, of St. Jude receives award for outstanding contributions to the pharmacy profession
William L. “Bill” Greene, PharmD, chief pharmaceutical officer, to receive the 2021 Shelby Rhinehart Public Service Lifetime Achievement Award.
Molecules in motion: researchers capture six new structures of the ribosome in action
St. Jude Children’s scientists have used smFRET and cyro-EM to capture structures of a biologic process through research that has implications for antibiotic development.
Discovery shows how tuning the immune system may enhance vaccines and ease disease
A metabolic control pathway that regulates T follicular helper cells offers targets for drugs to stimulate the adaptive immune response.
Genetic factors linked to response to common antiviral medications
Scientists at St. Jude and international collaborators have shown that the enzyme NUDT15 metabolizes ganciclovir and acyclovir, with genetic variants in this gene affecting how patients respond to these drugs.
Melanoma registry results shine light on rare pediatric cancer
St. Jude Children’s Research Hospital scientists created a registry for molecular analysis of pediatric melanoma that provides insight into treatment.
Studies reveal key process needed for cells to recover from stress
A pair of papers from St. Jude Children’s Research Hospital shows ubiquitination is needed for disassembly of stress granules, which are linked to neurodegenerative diseases.
Analysis reveals origins of a leukemia that straddles diagnostic categories
Research led by St. Jude and the Munich Leukemia Laboratory highlights molecular analysis as an approach to improve classification and diagnosis of acute leukemia.
Structure of enzyme that causes Parkinson’s promises pathways to new drugs
Enzyme LRRK2 is a biological switch whose mutation generates abnormal proteins in Parkinson’s patients.
Erica Sirrine named director of Social Work at St. Jude Children's Research Hospital
Grief and bereavement expert with years of building social work programs in academia will direct a growing program at St. Jude.
Gene therapy appears more cost effective than current treatments for severe hemophilia B
St. Jude Children’s Research Hospital provides the first gene therapy manufacturing and distribution cost report for hemophilia B.
St. Jude Children’s Research Hospital research featured at ASCO annual meeting
Scientists from St. Jude Children’s Research Hospital will present their original research and share their expertise at the American Society of Clinical Oncology (ASCO) annual meeting.
St. Jude, other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination on track
The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention.
M. Madan Babu elected to U.K. Academy of Medical Sciences
St. Jude director of Center of Excellence for Data Driven Discovery named a fellow of British medical association.
Researchers speed identification of DNA regions that regulate gene expression
St. Jude scientists have developed a highly efficient method to address a major challenge in biology—identifying the genetic ‘switches’ that regulate gene expression.
COVID-19 vaccine is associated with fewer asymptomatic SARS-CoV-2 infections
St. Jude COVID-19 screening and vaccination program for employees offers early evidence that vaccine protects against asymptomatic infection, which has fueled the pandemic.
St. Jude influenza research earns renewed NIH funding
Centers of Excellence for Influenza Research and Response at St. Jude earns nearly $9 million in funding.
St. Jude Children’s Research Hospital announces largest strategic expansion in its history targeting pediatric catastrophic diseases globally
Six-year plan to invest $11.5 billion with donor support to accelerate research and treatment worldwide.
Risk-directed childhood leukemia treatment takes a step forward
St. Jude findings highlight genomic analysis as a tool to extend risk-directed therapy and improve outcomes for children with the most common pediatric cancer.
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation.
Martine Roussel, Ph.D., elected to the AACR Academy Class of 2021
Martine Roussel, Ph.D., has been elected to the 2021 Class of Fellows of the American Association for Cancer Research.
ATRT molecular groups: looking at the biology from the clinic
Scientists at St. Jude Children’s Research Hospital are learning more about what the molecular groups of a rare pediatric brain tumor mean for clinical care.
St. Jude receives $9.9 million to advance cures for hard-to-treat pediatric cancer
St. Jude scientists have been selected for an international collaborative research effort to advance treatment for some leading causes of childhood cancer death.
Delaying the first spinal tap may lower risk of pediatric leukemia relapse
An international research team has identified clinical factors associated with the risk of central nervous system relapse in patients with the most common childhood cancer.
St. Jude and Washington University researchers receive $3.1 million NIH grant
Five-year grant will aid in the study of mechanisms underlying neurodegenerative diseases like ALS.
St. Jude launches program to boost HPV cancer prevention across the globe
St. Jude is dedicating staff and resources to focus on the prevention of human papillomavirus (HPV)-related cancers around the world through HPV vaccine awareness programming.
Connect to Protect launches plan to end HIV infections in Memphis
Organization details plan to eliminate new HIV infections in Memphis by 2030.
Researchers map metabolic signaling machinery for producing memory T cells
Discovery of a metabolic pathways that inhibit memory T cell production has potential for enhancing the immune system’s ability to fight infections and cancers.
Discovery offers potential for stripping tumors of T cell protection
St. Jude has discovered a mechanism that tumors use to switch on protective regulatory T cells, raising the potential for drug treatments that render tumors more vulnerable to cancer immunotherapy.
IARC and St. Jude announce partnership to expand global pediatric cancer registries
The project will expand and enhance data collection in low- and middle-income countries to support the global push to advance childhood cancer survival.
Study reveals mutations that drive therapy-related myeloid neoplasms in children
Research from scientists at St. Jude Children’s Research Hospital found mutations up to two years before cancer developed, showing an opportunity for early interventions.
Lockdowns, border closures and related measures could help stop future pandemics
New Zealand’s experience during the first wave of COVID-19 suggests nonpharmaceutical interventions should be considered to control severe viral respiratory outbreaks in the future.
Novel CAR-T cell receptor shows early promise for treatment of solid tumors
St. Jude Children’s Research Hospital scientists have created a CAR-T cell receptor designed to improve the effectiveness of immunotherapy for treatment of solid tumors.
From the clinic to the lab, understanding medulloblastoma relies on molecular profiling
A pair of research papers from St. Jude report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease.
Multidisciplinary research identifies novel targeted therapy for children with acute lymphoblastic leukemia
Scientists at St. Jude have revealed a potential treatment for T Cell ALL using a method that has implications for how cancer therapies are identified in the future.
MethylationToActivity: a deep learning framework for epigenetic research
Scientists at St. Jude Children’s Research Hospital have created a computational tool for inferring gene promoter activity and expression using DNA methylation data.
Researchers develop tool to ‘paint’ cancer genome and reveal tumor secrets
St. Jude scientists created a visualization tool to help investigators worldwide harness the scientific and clinical potential of genomic data.
St. Jude Cloud offers a data-sharing genomic ecosystem for the precision medicine era
St. Jude scientists created the largest cloud-based genomic resource for pediatric cancer and a data-sharing model to accelerate life-saving research.